Jefferies Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-2,039
Closed -$402 1420
2020
Q2
$402 Buy
2,039
+1,749
+603% +$362K ﹤0.01% 954
2020
Q1
$57K Sell
290
-3,540
-92% -$762K ﹤0.01% 1863
2019
Q4
$792K Buy
+3,830
New +$708K 0.01% 1583
2019
Q2
Sell
-23
Closed -$3K 2648
2019
Q1
$3K Buy
+23
New +$2.32K ﹤0.01% 2270
2018
Q4
Sell
-3,640
Closed -$409K 2298
2018
Q3
$409K Buy
+3,640
New +$385K ﹤0.01% 1711
2018
Q1
Sell
-10,745
Closed -$1.01M 2418
2017
Q4
$1.01M Buy
+10,745
New +$1.02M ﹤0.01% 1358

Other funds holding LKFT

Jefferies Group's LKFT Position: Q3 2020 in Review

Jefferies Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2020, closing a stake of 2,039 shares — an estimated $402 sold.

Jefferies Group first reported a position in LKFT in Q4 2017 and held it in 6 quarters. The position peaked at $1.01M in Q4 2017. 119 funds tracked by Wall St. Rank hold LKFT as of Q3 2020.

  • Jefferies Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 2,039 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2020, an estimated $402.
  • Jefferies Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2017 and held it in 6 quarters.
  • Jefferies Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.01M in Q4 2017.
  • 119 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.